AHCL • ISIN: INE0Y8W01017
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage.
Products:
Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs.
Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.
Competitive Strengths:
Strong product portfolio and scalable business.
Strong Promoters and Experienced Management Team.
High entry and exit barriers due to long customer approval cycles and strict product standards.
In-house Testing, Quality Control and Quality Assurance for quality control.
Focus on Quality, Environment, Health and Safety.
Funding capital expenditure requirements for Proposed Expansion
Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company
Funding the working capital requirements of the Company
General corporate purposes
Price Band
Min Investment
Lot Size
P/E Ratio
Issue Opens
26 Aug 2025
Issue Closes
29 Aug 2025
Allotment
1 Sept 2025
Listing
3 Sept 2025
Qualified Institutional Investors
7,656,340 / 9,975,000 shares
High Networth Individuals (Above ₹10 Lakhs)
5,865,296 / 1,330,000 shares
Non-Institutional Investors (Below ₹10 Lakhs)
6,076,364 / 665,000 shares
Retail Individual Investors
28,263,760 / 1,330,000 shares
Issue Type | BB |
Face Value | ₹10 |
Lead Managers | Interactive Financial Services Ltd. |
Min Quantity | 164 |
Max Quantity | 5,494 |
Company Promoters | Punitkumar R. rasadia Meet Atulkumar Vachhani Mamata punitkumar Rasadia are the promoters of the company. |
Website | |
Phone | +91 281 2562538 |
Address | Anlon Healthcare Ltd. |